ABBV-230 / OSE Immunotherapeutics, AbbVie - LARVOL DELTA

Agonist anti-FPR2 decreases neutrophil accumulation and initiates chronic inflammation resolution (IMMUNOLOGY 2026) - "Building on our expertise in engineering GPCRs specific mAb -demonstrated by OSE230 targeting ChemR23 - we developed a first-in-class mAb acting as a selective FPR2 agonist for the treatment of acute and chronic inflammatory diseases. A humanized VHH was generated and characterized for high affinity and specificity toward human FPR2. This first-in-class FPR2 specific agonist mAb introduces a novel strategy to actively drive long term resolution of inflammation. Its receptor specificity, strict agonist activity and robust preclinical efficacy on neutrophils and inflammatory monocytes recruitment position it as a promising therapeutic candidate for treating acute and chronic inflammatory disorders."

Acute Lung Injury • Endometriosis • Fibrosis • Gynecology • Immunology • Inflammation • Respiratory Diseases • Women's Health • FPR2 • GPRC6A • TNFA

OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi (GlobeNewswire) - "The Company will pause development of OSE‑230, allowing OSE to focus its resources on late‑stage, high‑potential assets lusvertikimab (OSE‑127) and Tedopi. These two assets are expected to generate multiple clinical catalysts over the next three years."

Discontinued • Pipeline update • Immunology • Non Small Cell Lung Cancer • Ovarian Cancer

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development (GlobeNewswire) - "Under the revised agreement, OSE Immunotherapeutics regains control of the early-stage development of the ABBV-230, while AbbVie maintains its rights to control future development and commercialization following successful completion of Phase 1. The revised approach reflects both parties’ continued enthusiasm for the potential of ABBV-230 and aligns development responsibilities with each company’s core strengths."

Licensing / partnership • Immunology • Inflammation

OSE Immunotherapeutics Reports First Half 2025 Financial Results (GlobeNewswire) - "Research and development expenses increased by 6.7% over the period, amounting to €14.8 million in the first half of 2025, compared to €13.9 million the prior year. This increase reflects our development programs moving forward, notably the ongoing Phase 3 trial of Tedopi – Artemia – actively recruiting...Operating loss amounted to €(15.8) million in the first half of 2025, compared to a profit of €63.3 million a year earlier, essentially reflecting an exceptional income in 2024 related to the AbbVie licensing agreement on OSE-230 and the amendment on the BI 765063 (OSE-172) agreement as well as the asset purchase agreement from the “cis-targeting” anti-PD1/cytokine platform by Boehringer Ingelheim."

Commercial • Immunology • Solid Tumor

AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation (PRNewswire) - "AbbVie Inc...and OSE Immunotherapeutics SA...announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage....Under the terms of the agreement, AbbVie will receive an exclusive global license to develop, manufacture and commercialize OSE-230. OSE Immunotherapeutics will receive a $48 million upfront payment and will be eligible to receive up to an additional $665 million in clinical development, regulatory and commercial milestones. In addition, OSE Immunotherapeutics will be eligible to receive potential tiered royalties on global net sales of OSE-230."

Licensing / partnership • Immunology • Inflammation

OSE Immunotherapeutics Announces Publication in Frontiers in Immunology on OSE-230, its Novel Agonist Therapy in Chronic Inflammation (Businesswire) - "OSE Immunotherapeutics SA...announced the publication of its latest peer-reviewed results on pro-resolutive monoclonal antibody OSE-230, a novel and innovative approach in the management of the resolution of chronic and severe inflammation, in the leading journal Frontiers in Immunology....The research demonstrated the reprogramming of TAM through the activation of ChemR23 by OSE-230. ChemR23 receptor strongly controls macrophage phenotype and its activation by OSE-230 results in major remodeling of the tumor immune microenvironment by limiting macrophages’ immunosuppressive functions, activating T lymphocyte activity as well as modifying the metastatic niche."

Preclinical • Immunology • Inflammation

OSE Immunotherapeutics Presents Update on BiCKI IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences (Businesswire) - "OSE Immunotherapeutics...presents scientific updates in oral and poster presentations selected for international conferences: at the Antibody Engineering & Therapeutics Europe 2023 Conference in Amsterdam, Netherlands (June 7), at the FOCIS 2023 Annual Meeting (June 20-23), the 4th Annual Cytokine-Based Drug Development Summit 2023 (June 27-29) and at the 3rd Annual Tumor Myeloid-directed Therapies Summit 2023 (July 18-20) in Boston, US. The communications feature the latest research on pre-IND programs for BiCKI®-IL-7 (bifunctional therapy targeting PD-1 and IL-7), CLEC-1 (new myeloid immune checkpoint) in immuno-oncology and for OSE-230 (first pro-resolutive monoclonal antibody) in chronic inflammation."

Preclinical • Burkitt Lymphoma • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Immunology • Inflammation • Liver Cancer • Lung Cancer • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • Thoracic Cancer

OSE Immunotherapeutics Announces Corporate Update and H1 2022 Results (Businesswire) - "A newly formed SAB combining the expertise of renowned scientific and international key-opinion leaders in the fields of immunology, immuno-oncology, inflammation and immunotherapy...The SAB includes...Dr. Jennifer Wargo...."